Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions

The CDC Advisory Committee on Immunization Practices (ACIP) recommended immunization with the recently licensed 13-valent pneumococcal conjugate vaccine (PCV13) for high-risk (immunocompromised) adults aged ≥19 years in 2012. This was in addition to the 23-valent pneumococcal polysaccharide vaccine...

Description complète

Détails bibliographiques

Auteurs principaux:	Jeffrey Vietri, James Harnett, Birol Emir, Erica Chilson
Format:	Artigo
Langue:	Inglês
Publié:	Taylor & Francis Group 2020-01-01
Collection:	Human Vaccines & Immunotherapeutics
Sujets:	13-valent pneumococcal vaccine pneumococcal conjugate vaccine pcv13 pneumococcal disease pneumococcal vaccines immunization risk factors
Accès en ligne:	http://dx.doi.org/10.1080/21645515.2019.1632683
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!